Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | CHRNA7 | P36544 | 8/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GFER | P55789 | 2/20 | 0.37 |
| ▸ | JUN | P05412 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.35 |
| ▸ | RELA | Q04206 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957889 | 0.90 | HPGD (0.36) | CHRNA7POLBSRC | |
| SCHEMBL20558385 | 0.83 | RXFP1 (0.46) | RXFP1CHRNA7POLBGFERJUN | |
| SCHEMBL20558359 | 0.79 | RXFP1 (0.43) | RXFP1CHRNA7POLBGFERJUN | |
| SCHEMBL4701156 | 0.77 | RXFP1 (0.40) | RXFP1CHRNA7POLBGFERJUN | |
| SCHEMBL20558353 | 0.76 | LCK (0.43) | RXFP1CHRNA7POLBJUNNFKB1 | |
| SCHEMBL27208466 | 0.76 | CHRNA7 (0.41) | RXFP1CHRNA7POLBJUNNFKB1 | |
| SCHEMBL22145328 | 0.76 | LCK (0.42) | RXFP1CHRNA7POLBJUNNFKB1 | |
| SCHEMBL22145718 | 0.75 | CHRNA7 (0.53) | RXFP1CHRNA7POLBJUNNFKB1 | |
| SCHEMBL2949398 | 0.74 | RXFP1 (0.51) | RXFP1CHRNA7POLBGFERJUN | |
| SCHEMBL20558241 | 0.74 | CHRNA7 (0.44) | CHRNA7POLBJUNNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763624-B2 | Substituted pyrazolo[3,4-d]pyrimidines as ACK-1 and LCK inhibitors | AMGEN INC. (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1926734-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS | Amgen Inc. (US) | 2008-06-04 | — | — | EP | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | AMGEN INC. (US) | 2007-03-29 | — | — | US | disclosed |
| WO-2007024680-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS | AMGEN INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| WO-2007024680-A1 | PYRAZOLOPYRIDINE AND PYRAZOLOPYRIMIDINE COMPOUNDS USEFUL AS KINASE ENZYMES MODULATORS | AMGEN INC. (US) | 2007-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072851-A1 | Pyrazolopyridine and pyrazolopyrimidine compounds | LCK, MAP4K5, TPMT | RXFP1 4446/4885CHRNA7 4725/4885POLB 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.